Isomorphic Labs raises record $5B in Series C funding for AI drug discovery
Alphabet-backed AI drug designer Isomorphic Labs has secured $5 billion in a Series C funding round, breaking the record for the largest private fundraise in biotechnology history. The fresh capital will be used to scale its AI simulation models and advance its internal oncology and immunology pipelines toward clinical trials.

Original image temporarily unavailable
According to BioSpace, AI-driven drug designer Isomorphic Labs has clinched $5 billion in Series C funding, more than doubling its $2.1 billion Series B raised in May and surpassing Altos Labs' previous $3 billion record set in 2022. The round was co-led by Greenoaks and Sequoia Capital, with continued backing from parent company Alphabet.
Founder and CEO Demis Hassabis stated that the new funds will accelerate the company's progress in building foundational biology models and driving therapeutic programs toward clinical trials. Although the company has not yet publicly disclosed any specific clinical assets, it reports having produced preclinical results for internal programs in oncology and immunology, alongside ongoing research partnerships with major pharmaceutical companies like Novartis, Eli Lilly, and Johnson & Johnson.
View selection rationale
Importance 88/100
About this brief
- Content type
- News summary
- Source type
- Publisher report
- Original source
- BioSpace Drug Development ↗
- Source published
- Process
- AI-assisted discovery, translation, summarisation, classification and scoring; standards and corrections are maintained by the editorial desk.
- Verification
- The original URL and publication metadata are retained. This brief is not independently fact-checked unless explicitly stated.
- Published by
- Polyemergence Editorial Desk · PolyEmergence Pte Ltd.
- Conflict disclosure
- No financial or commercial conflict declared.